Repligen Corporation
41 Seyon Street, Building #1
Suite 100
Waltham
Massachusetts
02495
United States
Tel: 781-250-0111
Fax: 781-250-0115
Website: http://www.repligen.com/
Email: info@repligen.com
298 articles about Repligen Corporation
-
Repligen Corporation to Present at 39th Annual J.P. Morgan Healthcare Conference
1/4/2021
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 39th Annual J.P. Morgan Healthcare conference being held January 11-14. Tony J. Hunt, President and Chief Executive Officer, will make a formal presentation on Wednesday, January 13, at 9:10 a.m. EST. A live webcast of the presentation will be accessible through the Investor R e l
-
Repligen Corporation Announces Closing of Public Offering of $312.2 Million, Including Full Exercise of Underwriters’ Option
12/10/2020
Repligen Corporation (NASDAQ: RGEN) today announced the closing of its previously announced underwritten public offering of an aggregate of 1.725 million shares of its common stock at a public offering price of $181 per share for gross proceeds,
-
Repligen Corporation Prices Public Offering of Shares of Common Stock
12/7/2020
Repligen Corporation (NASDAQ: RGEN) today announced the pricing of an underwritten public offering of 1.5 million shares of its common stock at a public offering price of $181 per share
-
Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock - Dec 07, 2020
12/7/2020
Repligen Corporation announced that it has commenced an underwritten public offering of 1.5 million shares of its common stock.
-
Repligen Reports Third Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance
11/5/2020
Reports record quarterly revenue of $94.1 million with strong margin expansion Overall revenue grew 35% year-over-year, with organic growth of 31% Raises revenue guidance to $ 348 -$ 352 million and overall revenue growth to 29%-30% for full year 2020, representing 23 %- 24 % organic growth Completes acquisition of Non-Metallic Solutions and an nounces a greement to a cquire b ioprocess s ystems i nnovator ARTeSYN Biosolutions
-
Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic Solutions
10/27/2020
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held ARTeSYN Biosolutions (“ARTeSYN”) for approximately $200 million, comprised of approximately $130 million in cash and approximately $70 million in Repligen common stock.
-
Repligen to Report Third Quarter 2020 Financial Results
10/22/2020
Webcast and Conference Call to Be Held Thursday, November 5, 2020 at 8:30 a.m. EST
-
Repligen and Navigo Proteins Announce Achievement of Key Milestone in Developing an Affinity Resin for the Purification of COVID-19 Vaccines
10/1/2020
Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH, a premier protein engineering company specializing in novel affinity ligand development, announced their successful development of an affinity ligand targeting the spike protein, to be utilized in the purification of COVID-19 vaccines.
-
Repligen Reports Second Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance
7/30/2020
Reports record quarterly revenue of $87.5 million Overall revenue grew 24% year-over-year, with organic growth of 19% Raises revenue guidance to $332-$340 million for full year 2020, representing 18%-21% organic growth Completes acquisition of silicone molding and tubing manufacturer Engineered Molding Technology WALTHAM, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today repor
-
Repligen to Report Second Quarter 2020 Financial ResultsWebcast and Conference Call to Be Held Thursday, July 30, 2020 at 8:30 a.m. EDT
7/15/2020
Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2020 financial results on Thursday, July 30, 2020. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three- and six- month reporting periods ended June 30, 2020. The conference call will be accessible by dialing toll-free (844)
-
Repligen Announces Agreement to Acquire Engineered Molding TechnologyExpands Single-Use Portfolio with Expertise in Silicone Molding and Tubing
6/29/2020
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into an agreement to acquire Albany, New York based Engineered Molding Technology (“EMT”), an innovator and manufacturer of single-use silicone assemblies and components used in the manufacturing of biologic drugs. EMT’s standard and custom molded and over-molded connectors and silicone tubing products
-
Repligen Appoints Carrie Eglinton Manner to Board of Directors
6/15/2020
Repligen Corporation (NASDAQ:RGEN) today announced the appointment of healthcare industry executive Carrie Eglinton Manner to its Board of Directors.
-
Repligen Reports First Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance
5/6/2020
Reports record quarterly revenue of $76.1 million Overall revenue grew 25% year-over-year, with organic growth of 16% Strong order load through first four months
-
Repligen to Report First Quarter 2020 Financial ResultsWebcast and Conference Call to Be Held Wednesday, May 6, 2020 at 8:30 a.m. EDT
4/22/2020
Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2020 financial results on Wednesday, May 6, 2020. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three-month reporting period ended March 31, 2020. The conference call will be accessible by dialing toll-free (844) 701-1063
-
Repligen Appoints Rohin Mhatre, Ph.D. to Board of Directors
2/27/2020
Repligen Corporation (NASDAQ:RGEN) today announced the appointment of life sciences industry executive Rohin Mhatre, Ph.D., to its Board of Directors.
-
Repligen Reports Fourth Quarter and Full Year 2019 Financial Results
2/20/2020
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter and full year 2019.
-
Repligen to Report Fourth Quarter and Full Year 2019 Financial ResultsWebcast and Conference Call to Be Held Thursday, February 20, 2020 at 8:30 a.m. EST
2/6/2020
WALTHAM, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2019 financial results on Thursday, February 20, 2020. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EST to discuss business updates and financial results for the three- and twelve-month reporting periods ended December 31, 2019. The conference call will be accessible b
-
Repligen to Present at the 38th Annual J.P. Morgan Healthcare Conference
1/7/2020
Tony J. Hunt, Repligen’s president and chief executive officer, is scheduled to present a company overview on Wednesday, January 15, 2020 at 11:30 a.m. PT.
-
Repligen Reports Third Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance
10/31/2019
Reports quarterly revenue of $69.4 million, representing 40% reported growth and 28% organic growth year-over-year
-
Repligen to Report Third Quarter 2019 Financial ResultsWebcast and Conference Call to Be Held Thursday, October 31, 2019 at 8:30 a.m. EDT
10/23/2019
The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three- and nine-month reporting periods ended September 30, 2019.